研究者詳細 - 安田　満

Misc - 安田　満

分割表示 155 件中 121 - 140 件目／全件表示 >>

S Ishihara, M Yasuda, S Ito, S Maeda, T Deguchi

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS ( ELSEVIER SCIENCE BV ) 24 S23 - S27 2004年09月

Mycoplasma genitalium was first isolated from two men with non-gonococcal urethritis (NGU) and thereafter shown to produce urethritis in subhuman primates, inoculated intraurethrally. This mycoplasma has been detected significantly more often in patients with acute NGU, particularly in patients with non-chlamydial NGU, than in subjects without urethritis. The prevalence of M. genitalium-positive non-chlarnydial NGU ranges from 18 to 46% of all non-chlamydial NGU cases. In addition, the persistence of M. genitalium in the urethra after antimicrobial chemotherapy is associated with persistence or recurrence of NGU. The various results reported to date tend to support the proposition that M. genitalium is a pathogen of NGU. M. genitalium is highly susceptible to tetracyclines, macrolides, and some new fluoroquinol ones, but the clinical data on the chemotherapy in M. genitalium-positive NGU is extremely limited. Because of the possible association between the post-treatment presence of M. genitalium in the urethra and persistent or recurrent NGU, the eradication of this mycoplasma from the urethra is essential in the management of patients with M. genitalium-positive NGU. Further studies are required to establish the optimal chemotherapy for M. genitalium-positive NGU. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

DOI PubMed

Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones

M Ito, M Yasuda, S Yokoi, SI Ito, Y Takahashi, S Ishihara, SI Maeda, T Deguchi

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ( AMER SOC MICROBIOLOGY ) 48 ( 8 ) 3185 - 3187 2004年08月

DOI PubMed

Association of Ureaplasma urealyticum (Biovar 2) with nongonococcal urethritis

T Deguchi, T Yoshida, T Miyazawa, M Yasuda, M Tamaki, H Ishiko, SI Maeda

SEXUALLY TRANSMITTED DISEASES ( LIPPINCOTT WILLIAMS & WILKINS ) 31 ( 3 ) 192 - 195 2004年03月

Background: The tiny (T)-strain mycoplasmas, designated in 1974 as Ureaplasma urealyticum, have been divided into 2 species, Ureaplasma parvum (biovar 1) and U. urealyticum (biovar 2), but association of each of these species with nongonococcal urethritis (NGU) remains unclear. Goal: The goal of this study was to determine whether U. parvum (biovar 1) or U. urealyticum (biovar 2) is associated with NGU. Study Design: The prevalences of U. parpum (biovar 1) and U. urealyticum (biovar 2) in 572 patients with urethritis were compared with those in 141 men without urethritis. Results: The prevalence of U. urealyticum (biovar 2) in men with NGU (15.8%) or with nonchlamydial NGU (18.0%) was significantly higher than that in men without urethritis (7.8%). The prevalence of U. parvum (biovar 1) in men with NGU (8.5%) or with nonchlamydial NGU (11.1%) did not differ significantly from that in men without urethritis (13.5%). Conclusion: Our results showed a significant association between U. urealyticum (biovar 2) and NGU. They also suggest that the presence of U. parvum (biovar 1) in the male urethra might be the result of colonization.

DOI PubMed

Nationwide survey of urogenital tuberculosis in Japan

Keita Nakane, Keita Nakane, Mitsuru Yasuda, Mitsuru Yasuda, Takashi Deguchi, Takashi Deguchi, Satoshi Takahashi, Satoshi Takahashi, Kazushi Tanaka, Kazushi Tanaka, Hiroshi Hayami, Hiroshi Hayami, Ryoichi Hamasuna, Ryoichi Hamasuna, Shingo Yamamoto, Shingo Yamamoto, Soichi Arakawa, Soichi Arakawa, Tetsuro Matsumoto, Tetsuro Matsumoto

International Journal of Urology 21 ( 11 ) 1171 - 1177 2004年01月 [ 国際誌 ]

© 2014 The Japanese Urological Association. Objectives: To determine current epidemiology and treatment patterns of urogenital tuberculosis in Japan. Methods: A questionnaire was sent to the urological departments of 1203 Japanese hospitals. Clinical data was reviewed retrospectively; no time range was specified. Results: Of the 1203 hospitals, 399 returned questionnaires with information about 355 urogenital tuberculosis patients. Of the 399, 153 institutions reported at least one patient, and 201 patients were identified between 2000 and 2007. Infections were located in the kidneys (n=242), ureter (n=96), bladder (n=100), epididymis or testes (n=81) and prostate (n=9). Conclusions: Urogenital tuberculosis is rare in Japan, but patients do exist, and we should not ignore them.

DOI PubMed

Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis

Shigeaki Yokoi, Mitsuru Yasuda, Shin-Ichi Ito, Yoshihito Takahashi, Satoshi Ishihara, Takashi Deguchi, Shin-Ichi Maeda, Yasuaki Kubota, Masayoshi Tamaki, Hideto Fukushi

Journal of Infection and Chemotherapy ( Springer Japan ) 10 ( 5 ) 262 - 267 2004年

Twenty-three clinical strains of Chlamydia trachomatis were isolated from men with chlamydial nongonococcal urethritis and examined for the presence of fluoroquinolone resistance-associated alterations in GyrA and ParC. The minimum inhibitory concentrations (MICs) of fluoroquinolones, erythromycin, and tetracycline were determined for 6 of the 23 isolates. In 12 of the 23 isolates, a single amino-acid change was found in GyrA, and in 1 isolate, two amino acids were changed. In all 23 isolates, an Arg-83-to-Gly substitution was observed in ParC, and in 3 isolates, an additional amino-acid change was found. Some changes occurred within the quinolone resistance-determining regions (QRDRs) of GyrA and ParC, but not at positions critical for fluoroquinolone resistance. Of the 6 isolates for which MICs of the agents were determined, 1 isolate had a Cys-66 → Arg substitution in GyrA, and all had the Arg-83 → Gly substitution in ParC. However, all 6 isolates were susceptible to fluoroquinolones. First-pass urine specimens were obtained from two men who were positive for C. trachomatis after levofloxacin treatment, and the gyrA and parC genes of C. trachomatis were amplified by polymerase chain reaction (PCR) and examined for fluoroquinolone resistance-associated mutations. Pre- and post-treatment C. trachomatis persisting in each of them had identical amino-acid sequences in the QRDR of GyrA and ParC. Further, the substitutions found in GyrA and ParC were not located at positions critical for fluoroquinolone resistance. The present study suggests that fluoroquinolone resistance-associated alterations in GyrA and ParC may be uncommon in clinical strains of C. trachomatis.

DOI PubMed

Treatment of uncomplicated gonococcal urethritis by double-dosing of 200mg cefixime at a 6-h interval

Takashi Deguchi, Mitsuru Yasuda, Shigeaki Yokoi, Ken-Ichiro Ishida, Masayasu Ito, Satoshi Ishihara, Ken Minamidate, Yoshimasa Harada, Kanhin Tei, Kentaro Kojima, Masayoshi Tamaki, Shin-Ichi Maeda

Journal of Infection and Chemotherapy ( Springer Japan ) 9 ( 1 ) 35 - 39 2003年

The efficacy of antimicrobial regimens for the treatment of uncomplicated gonococcal urethritis depends partially upon the period of time (therapeutic time) during which the drug concentration in the blood after the concentration peak is greater than four times the minimum inhibitory concentration for 90% of clinical isolates of Neisseria gonorrhoeae (MIC90). A therapeutic time of at least 10h is suggested as an important determinant for elimination of 95% or more of the infection. In this study, therapeutic times for a single 400-mg dose of cefixime at various MIC90s were calculated, and pharmacokinetic profiles of double-dosing of 200mg cefixime at various intervals were simulated. Subsequently, a dosing interval of 6h was tested in 6 healthy Japanese men, and then 93 Japanese men with gonococcal urethritis were treated with a regimen of two 200-mg doses of cefixime given at a 6-h interval. For a single dose of 400mg cefixime, therapeutic times were calculated to be 12.8, 9.1, 5.4, and 1.7h for MIC90s of 0.06, 0.125, 0.25, and 0.5 μg/ml, respectively. In the simulation study of double-dosing of 200mg cefixime at a 6-h interval, the therapeutic times for the MIC90s of ≤0.125 μg/ml were longer than 10h. Of the 93 patients, 68 were evaluated for microbiological outcome, and N. gonorrhoeae was eradicated in 60 (88.2%). The MIC90 of cefixime for the 61 isolates tested was 0.125 μg/ml. All strains with MICs of ≤0.06 μg/ml were eradicated, whereas 8 of 16 strains with MICs of ≥0.125 μg/ml persisted after treatment. This regimen would not be effective against infection by strains exhibiting cefixime MIC90s of ≥0.125 μg/ml. For such strains, a different regimen with a higher dose of cefixime would be required.

DOI PubMed

Urinary tract-derived Escherichia coli resistant to co-trimoxazole in Japan, where the drug is seldom used for treating acute urinary tract infections

S Ishihara, S Yokoi, N Masue, T Yamada, Y Minamidate, M Yasuda, M Nakano, T Deguchi

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY ( OXFORD UNIV PRESS ) 49 ( 5 ) A881 - 882 2002年05月

速報，短報，研究ノート等（学術雑誌）

DOI PubMed

Antimicrobial activity of imipenem against isolates from complicated urinary tract infections

Satoshi Ishihara, Toru Yamada, Shigeaki Yokoi, Masayasu Ito, Mitsuru Yasuda, Masahiro Nakano, Yukimichi Kawada, Takashi Deguchi

International Journal of Antimicrobial Agents 19 ( 6 ) 565 - 569 2002年

Antimicrobial activity of imipenem was measured using 4725 strains isolated from patients with complicated urinary tract infections (CUTIs) between 1988 and 2000. Imipenem was inactive against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, Enterococcus faecium and some non-fermenting Gram-negative rods. Resistant strains (MIC> 16 mg/l) were observed in Staphylococcus haemolyticus (22%), Enterococcus faecalis (4%), Enterococcus avium (8%), Serratia marcescens (5%) and Pseudomonas aeruginosa (7%). Although the prevalence of imipenem-resistant strains of S. aureus, S. epidermidis and P. aeruginosa was sporadically high in some years, no steady increase was seen over the period. Resistant strains were rare in other major uropathogenic species. These results suggest that imipenem is still one of the most reliable antimicrobial drugs. © 2002 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.

DOI PubMed

In vivo selection of Pseudomonas aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection

Masahiro Nakano, Mitsuru Yasuda, Shigeaki Yokoi, Yoshihito Takahashi, Satoshi Ishihara, Takashi Deguchi

Urology 58 ( 1 ) 125 - 128 2001年

Objectives. To present a case of fluoroquinolone treatment failure in urinary tract infection caused by Pseudomonas aeruginosa, accompanied by in vivo selection of the post-treatment isolate that showed decreased susceptibilities to fluoroquinolones, and to report fluoroquinolone resistance mechanisms in the post-treatment isolate. Methods. A patient with urinary tract infection was treated with a suboptimal dose of a fluorinated quinolone, gatifloxacin. P. aeruginosa strains were isolated before and after fluoroquinolone treatment. The pretreatment and post-treatment isolates were examined for relatedness by arbitrarily primed polymerase chain reaction. For these isolates, the minimum inhibitory concentration of antimicrobial agents was determined and mutations in the target genes (gyrA and parC) and regulatory genes (mexR and nfxB) for drug efflux pumps were analyzed. Results. Failure of fluoroquinolone treatment of urinary tract infection was observed. The post-treatment isolate, which was assumed to be isogenic to the pretreatment isolate, exhibited fourfold to 16-fold increases in the MIC of fluoroquinolones. In this isolate, a new mutation, not observed in the pretreatment isolate, was found only in the gyrA gene, resulting in an amino acid change of aspartic acid to asparagine in codon 87 of GyrA. Conclusions. The P. aeruginosa isolate that was initially susceptible to fluoroquinolones showed decreased susceptibility to fluoroquinolones after treatment with a suboptimal dose of one fluoroquinolone. In the post-treatment isolate, the alteration of GyrA would be responsible for the decreased susceptibility to fluoroquinolones. We should be aware that inappropriate use of fluoroquinolones could select such a strain harboring a quinolone resistance-associated alteration of DNA gyrase. Copyright © 2001 Elsevier Science Inc.

DOI PubMed

A clinical study on active vitamin D pulse therapy in hemodialysis patients with secondary hyperparathyroidism

Hidetoshi Ehara, Shin-Ichi Nezasa, Noriyasu Hagiwara, Tohru Yamada, Mitsuru Yasuda, Yoshinori Nishino, Yasuyuki Nishida, Yoshito Takahashi, Satoshi Ishihara, Takashi Degughi

Acta Urologica Japonica 46 ( 3 ) 165 - 168 2000年03月

The oral active vitamin D pulse therapy was performed for 20 chronic hemodialysis patients with secondary hyperparathyroidism (2°HPT). Before pulse therapy, all patients showed high-turnover bone diseases, elevated serum alkaline phosphatase (Alp) and elevated serum parathyroid hormone (PTH). They had at least one parathyroid gland detected by ultrasonography. In one patient, serum PTH level did not decrease during three months. In five patients, hypercalcemia was observed so that the pulse therapy was withdrawn. Another patient was resistant to the second pulse therapy for recurrence of 2°HPT. Total parathyroidectomy and autotransplantation was performed in these seven patients. The size of parathyroid gland in patients undergoing surgical treatment was significantly larger than those estimated by ultrasonography in patients successfully treated with pulse therapy (p< 0.005). In all patients with surgical treatment, the conventional oral active vitamin D therapy was performed with caution to hypercalcemia preoperatively. The preoperative Alp levels decreased compared with those of at the beginning of the pulse therapy. Postoperatively, the total amount of intravenous administered calcium decreased, and serum calcium levels were easily controlled.

PubMed

In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV

Mitsuru Yasuda, Hideyuki Fukuda, Shigeaki Yokoi, Satoshi Ishihara, Yukimichi Kawada, Takashi Deguchi

Journal of Urology ( Lippincott Williams and Wilkins ) 164 ( 3 I ) 847 - 851 2000年

Purpose: We attempted to select increasingly fluoroquinolone-resistant strains of Neisseria gonorrhoeae in vitro and to assess whether selected mutants harbored alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV, which were analogous to those in fluoroquinolone-resistant clinical isolates. Materials and Methods: A fluoroquinolone-susceptible strain was exposed to norfloxacin in vitro. Selected mutants were sequentially exposed to norfloxacin, and this procedure was repeated. For 11 mutants, minimum inhibitory concentrations (MICs) of antimicrobial agents were determined, and mutations in the region corresponding to the quinolone resistance-determining region (QRDR) of the Escherichia coli gyrA gene and the analogous region of the parC gene were analyzed. Results: Mutants obtained in one step exhibited significantly increased MICs of norfloxacin, ofloxacin and ciprofloxacin and had a single amino acid change in GyrA. Two- step mutants exhibited significantly higher norfloxacin MICs. Three of four two-step selected strains had single amino acid changes in both GyrA and ParC. Three-step mutants exhibited further increases in fluoroquinolone MICs and were assigned to the ciprofloxacin-resistant category. Two had a double amino acid change in GyrA, and one had a double GyrA change and a single amino acid change in ParC. Conclusion: We selected fluoroquinolone-resistant strains that carried GyrA and ParC alterations analogous to those in clinical isolates. The serial accumulation of changes in the QRDR of GyrA and the analogous region of ParC was associated with a stepwise increase in fluoroquinolone resistance, although the development of additional alterations in other regions of GyrA and ParC or other mechanisms of fiuoroquinolone resistance also might contribute to the enhancement in fluoroquinolone resistance. The clinical emergence of fluoroquinolone-resistant strains may be due to in- vivo stepwise selection of strains with genetic alterations in GyrA and ParC, as observed here in the in-vitro selection of fluoroquinolone-resistant mutants.

PubMed

Development of a rapid assay for screening point mutations associated with quinolone resistance in the Pseudomonas aeruginosa parC gene

Takashi Deguchi, Masayoshi Yamaha, Masahiro Nakano, Mitsuru Yasuda, Yoshinori Nishino, Satoshi Ishihara, Yukimichi Kawada

Journal of Infection and Chemotherapy ( Springer Japan ) 6 ( 1 ) 26 - 29 2000年

To detect quinolone resistance-associated mutations within the Ser-80 and Glu-84 codons of the Pseudomonas aeruginosa parC gene, we developed a rapid and simple assay based on polymerase chain reaction (PCR) amplification of the region of the parc gene containing the mutation sites and digestion of the PCR products with a restriction enzyme. The mutations generating alterations at Ser-80 and Glu-84 were detected as restriction fragment length polymorphisms of the PCR products digested with HinfI. Among 22 clinical isolates tested by this assay, mutations at the Ser-80 and Glu-84 codons were detected in all 10 isolates in which the presence of the mutations had been confirmed previously by DNA sequencing. This rapid and simple assay could be a useful screening device for genetic alterations associated with resistance to quinolones in the P. aeruginosa parc gene.

DOI PubMed

Clinical study of gatifloxacin in the treatment of male urethritis

Y. Kawada, T. Deguchi, M. Yasuda, I. Saito, M. Yoshida, S. Maeda, K. Tei, Y. Harada, S. Matsuda, Y. Nagatani, H. Kojima, T. Tahara, Y. Hosoi, T. Kawamura, Y. Kunisawa, R. Miyamura

Japanese Journal of Chemotherapy 47 786 - 793 1999年12月

The clinical efficacies of gatifloxacin (GFLX), a new 8- methoxyquinolone, on male urethritis were investigated. The subjects were 45 patients with gonococcal urethritis, 7 with gonococcal-chlamydial urethritis, 75 with chlamydial urethritis and 44 with nongonococcal-nonchlamydial urethritis. GFLX was administered orally at a dose of 200 mg twice a day for 3 days to the patients with gonococcal urethritis, and for 7 to 14 days to those with chlamydial urethritis and nongonococcal-nonchlamydial urethritis. Thirty-six patients with gonococcal urethritis, 33 patients with chlamydial urethritis and 20 patients with nongonococcal-nonchlamydial urethritis were assessable according to the criteria of the Japanese UTI Committee. The overall clinical responses were excellent in 30 cases and moderate in 6 cases with gonococcal urethritis, excellent in 25 cases, moderate in 7 cases and poor in i case with chlamydial urethritis, and excellent in all cases with nongonococcal-nonchlamydial urethritis, showing an overall efficacy rate of 100%, 97.0%, and 100%, respectively. MIC90 of GFLX against 36 strains of Neisseria gonorrhoeae isolated in this study, was 0.063 μg/mL, and its activity was 4-

DOI

膀胱癌・前立腺癌に対するリザーバー動注化学療法の経験

高橋義人, 山本直樹, 出口隆, 栗山学, 楊睦正, 安田満, 仲野正博, 河田幸道, 竹内敏視, 篠田育男

泌尿器科紀要 ( 泌尿器科紀要刊行会 ) 45 ( 2 ) 159 - 161 1999年02月

他臓器の合併症を初めとしてなんらかの理由で手術施行が不可能であった進行性膀胱癌15例,膀胱全摘除術試行後の骨盤内再発10例に対しSeldinger法に準じて皮下埋没型リザーバーシステムを設置し動注化学療法を施行.局所再燃前立腺癌23例,内分泌療法不応性局所進行型前立腺癌5例に対してリザーバーを動注化学療法を施行.使用薬剤は,methotrexate,cis-platinum,adriamycinを用いた動注化学療法を入院で施行,外来通院中で可能な症例には5-FUもしくはcarboplatinを維持化学療法として施行.膀胱癌で平均6回,前立腺癌で平均4回施行.局所が制癌されている期間には,遠隔部位での増悪は認めなかった.膀胱癌でPR18例NC7例,前立腺癌でPR11例,NC14例.奏効期間は,膀胱癌で最大46ヵ月,中央値23ヵ月,前立腺癌で最大32ヵ月,中央値12ヵ月.副作用は,全身化学療法に比較して軽度であったA clinical study was performed on the efficacy of intra-arterial chemotherapy using a reservoir system for advanced urological malignancies. The reservoir system was indwelted in the femoral subcutaneous layer by Seldinger's method. Fifteen cases of inoperable complicated advanced bladder cancer and 10 cases of postoperative local recurrent bladder cancer were administered intra-arterial chemotherapy using a reservoir system. Then, 23 cases of local relapsed prostate cancer and two cases of endpocrine-resistant prostate cancer were administered the chemotherapy. The administered anti-cancerous agents were methotraxate, cis-platinum and adriamycin, then 5-FU or carboplatin was administered as maintenance therapy. The mean number of courses of chemotherapy was six for bladder cancer and four for prostate cancer. During stabilization of the local lesion, no distant deterioration was recognized. The overall clinical efficacy was a positive response (PR) and no change (NC): for 18 and 7 cases of bladder cancer, and 11 and 14 cases of prostate cancer, respectively. The median duration of stabilization was 23 months for bladder cancer and 12 months for prostate cancer. The adverse effects were fever than those with systemic chemotherapy.

CiNii

尿路性器感染症における mycoplasma の病原的意義

安田満, 宇野雅博, 出口隆

日本マイコプラズマ学会雑誌 = Japanese Journal of Mycoplasmology 25 1 - 8 1998年12月

CiNii

Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis

Zhiyu Li, Takashi Deguchi, Mitsuru Yasuda, Takeshi Kawamura, Emiko Kanematsu, Yoshinori Nishino, Satoshi Ishihara, Yukimichi Kawada

Antimicrobial Agents and Chemotherapy 42 ( 12 ) 3293 - 3295 1998年12月

PubMed

In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC (vol 40, pg 907, 1997)

T Deguchi, M Yasuda, T Kawamura, Y Takahashi, E Okezaki, O Nagata, H Kato, Y Kawada

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY ( OXFORD UNIV PRESS ) 41 ( 6 ) 672 - 673 1998年06月

その他

Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis

Emiko Kanematsu, Takashi Deguchi, Mitsuru Yasuda, Takeshi Kawamura, Yoshinori Nishino, Yukimichi Kawada

Antimicrobial Agents and Chemotherapy 42 ( 2 ) 433 - 435 1998年02月

PubMed

Erratum: In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Klebsiella pneumoniae and Enterobacter cloacae with fluoroquinolone resistance-associated amino acid alterations in GyrA and ParC (Journal of Antimicr

T. Deguchi, M. Yasuda, T. Kawamura, Y. Takahashi, E. Okezaki, O. Nagata, H. Kato, Y. Kawada

Journal of Antimicrobial Chemotherapy 41 672 - 673 1998年01月

Significance of Stenotrophomonas maltophilia in urinary tract infections

Satoshi Ishihara, Mitsuru Yasuda, Masahiro Nakano, Shigehiko Ozeki, Takashi Deguchi, Yoshihito Ban, Yukimichi Kawada

Journal of Infection and Chemotherapy ( Springer Japan ) 4 ( 1 ) 20 - 23 1998年

Bacteriuria of Stenotrophomonas maltophilia, a new name for Xanthomonas maltophilia, is not common. During a 7-year study period, the medical records of 26 patients were retrospectively analyzed. All patients had several underlying diseases and previous antimicrobial treatments. S. maltophilia spontaneously regressed and was thought to be colonized in most of our patients. This organism is resistant to most broad-spectrum antibiotics, except for minocycline and latamoxef. Although S. maltophilia is thought to be a colonizer in the urinary tract, it should be viewed with special concern because of its resistance to antibiotics. © JSC/CLJ 1998.

DOI

　前のページ - 次のページ　

<安田 満>

Misc - 安田 満

<安田　満>

Misc - 安田　満